- Home
- GLSI vs IRWD Comparison
GLSI vs IRWD Comparison
Compare GLSI & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLSI
- IRWD
- Stock Information
- Founded
- GLSI 2006
- IRWD 1998
- Country
- GLSI United States
- IRWD United States
- Employees
- GLSI N/A
- IRWD N/A
- Industry
- GLSI Biotechnology: Pharmaceutical Preparations
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- GLSI Health Care
- IRWD Health Care
- Exchange
- GLSI Nasdaq
- IRWD Nasdaq
- Market Cap
- GLSI N/A
- IRWD 150.9M
- IPO Year
- GLSI 2020
- IRWD 2010
- Fundamental
- Price
- GLSI $9.43
- IRWD $0.71
- Analyst Decision
- GLSI Strong Buy
- IRWD Buy
- Analyst Count
- GLSI 1
- IRWD 5
- Target Price
- GLSI $39.00
- IRWD $4.94
- AVG Volume (30 Days)
- GLSI 71.1K
- IRWD 4.0M
- Earning Date
- GLSI 05-19-2025
- IRWD 05-07-2025
- Dividend Yield
- GLSI N/A
- IRWD N/A
- EPS Growth
- GLSI N/A
- IRWD N/A
- EPS
- GLSI N/A
- IRWD N/A
- Revenue
- GLSI N/A
- IRWD $317,676,000.00
- Revenue This Year
- GLSI N/A
- IRWD N/A
- Revenue Next Year
- GLSI N/A
- IRWD N/A
- P/E Ratio
- GLSI N/A
- IRWD N/A
- Revenue Growth
- GLSI N/A
- IRWD N/A
- 52 Week Low
- GLSI $8.06
- IRWD $0.59
- 52 Week High
- GLSI $18.75
- IRWD $8.23
- Technical
- Relative Strength Index (RSI)
- GLSI 43.49
- IRWD 30.30
- Support Level
- GLSI $9.20
- IRWD $0.88
- Resistance Level
- GLSI $9.82
- IRWD $0.98
- Average True Range (ATR)
- GLSI 0.57
- IRWD 0.10
- MACD
- GLSI 0.02
- IRWD 0.01
- Stochastic Oscillator
- GLSI 19.21
- IRWD 14.47
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.